Abstract 1938P
Background
The prognosis for young patients with papillary thyroid cancer is usually good unless distant metastases occur. Lung metastasis is one of the most common distant metastases of thyroid cancer, but lacks an effective way to predict it. Our aim was to develop a nomogram to predict the possibility of lung metastases in patients with papillary thyroid cancer under 55 years old, considering the genetic background.
Methods
243 patients with papillary thyroid cancer under 55 years old were collected from January 2017 to June 2020 and randomly divided (7:3) into the training (n=170) and validation (n=73) groups. Univariate and multivariate binary logistic regression analyses were conducted, based on which a nomogram related to the risk of lung metastases of thyroid cancer was built in the training group. The nomogram was evaluated by calibration curves and decision curve analysis (DCA), the concordance index (C-index) and area under the receiver operating characteristic (ROC) curve (AUC) in the training and validation groups, respectively.
Results
T stage, Single-side invasion, TERT mutation and BRAF mutation were the independent prognostic factors for the construction of the nomogram. The C-index of the nomogram was 0.89 and 0.88 in the training and validation groups, respectively. The AUC, DAC, and calibration curves for nomogram showed satisfactory results. The cut-off value was 0.229, with a sensitivity of 0.829 and a specificity of 0.793.
Conclusions
A nomogram with good predictive capability has been established and validated, which may do a favor to predict lung metastases of young patients with papillary thyroid cancer in clinical practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The science and technology innovation Program of Hunan Province (2023SK4043).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1465P - Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy
Presenter: Takeru Wakatsuki
Session: Poster session 18
1468P - cGAS-driven inflammation in chromosomally unstable oesophagogastric adenocarcinoma
Presenter: Eileen Parkes
Session: Poster session 18
1469P - Development of an efficacy prediction model for concurrent chemoradiotherapy in esophageal squamous cell carcinoma using deep learning and multimodal data integration
Presenter: Xin Yang
Session: Poster session 18
1470TiP - Phase I trial of intraperitoneal infusion of GAIA-102 of NK-Like CD3-negative cells for gastric/pancreatic cancer
Presenter: Eiji Oki
Session: Poster session 18
1471TiP - MK-2870-015: A phase III study of trophoblast antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) vs treatment of physician’s choice (TPC) for previously treated metastatic gastroesophageal adenocarcinoma (GEA)
Presenter: Zev Wainberg
Session: Poster session 18
1472TiP - Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma: A prospective, multicenter study of the FLOT-AIO Gastric Cancer Group – The IKF-057/ PRESTO trial
Presenter: Nils Homann
Session: Poster session 18
1473TiP - Neoadjuvant SOX combined with cadonilimab (AK104) for PD-L1 negative upper GC/GEJC patients
Presenter: Zhen Yuan
Session: Poster session 18
1474TiP - A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ)
Presenter: Ziyu Li
Session: Poster session 18